Navigation Links
U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
Date:10/18/2007

focused, integrated discovery and development companies in Europe. Following a merger between Pfizer and Pharmacia, the rights to Brostallicin were assigned to NMS which continued its development and ultimately licensed worldwide rights to Systems Medicine.

About Systems Medicine (SM)

In July 2007, CTI acquired Systems Medicine (SM), a privately-held oncology company, in a stock-for-stock merger. SM applies a systems biology approach to drug development, combining pharmacogenomics and bioinformatics with experienced preclinical, clinical, and regulatory expertise to find and exploit a specific cancer's context of vulnerability. Specifically, SM defines the molecular and genetic alterations (context) that cause cancer cells to be particularly sensitive (vulnerable) to a drug or combination of drugs-the context of vulnerability.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.cticseattle.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of brostallicin include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with brostallicin in particular including, without limitation, the potential failure of brostallicin to prove safe and effective for treatment of solid tumors, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, costs of developing, producing and selling brostallicin, and the risk factors listed or described from time to time in
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Radiation Overdose at the Beatson Oncology Centre
2. Videoconferencing, an impetus to Pediatric Oncology
3. Oncology Drug Pemnat Launched By NATCO
4. United Biotech Launches New Oncology Division
5. Bengal Teenager to Participate in World Oncology Camp
6. CMPMedica Adds Oncology Search Engine to SearchMedica.com
7. Bird Flu: Orissa Initiates Protective Measures
8. Biota Initiates Drug Testing War against Common Cold
9. Russia Initiates Mass Vaccination Of Poultry To Restrict Bird Flu
10. Government Initiates A Program To Curb HIV
11. Alteon Initiates Phase 2 Trial of ALT-2074 in Diabetes and Haptoglobin 2-2
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... 2015 Mesa, Arizona (PRWEB) May ... Ag Ventures, Inc. (MAV), an investor backed Colorado ... Arizona based Phoenician Engineering subsidiary three times since ... recently achieved profitability from operations, within one year ... at the end of 2014 to over 500 ...
(Date:5/6/2015)... Established by the Arthritis Foundation, the month of ... Americans who suffer from arthritis. Many who battle this ... symptoms. Medicationdiscountcard.com is proud to offer a prescription ... costs of these necessary prescriptions. , Non-Steroidal Anti-Inflammatory Drugs ... and inflammation in the joints associated with arthritis. Certain ...
(Date:5/6/2015)... Most people in the United States will need at ... age 65. But less than half of people in their ... about it, reports the May 2015 Harvard Health Letter ... is losing control over the care they'll receive. "Many people ... a professor of health care policy at Harvard Medical School. ...
(Date:5/6/2015)... Novodiax announced today that they will ... with Ed Begley Jr., airing via Discovery Channel ... , This segment will explore Novodiax, a company ... will learn about Novodiax’s polymer detection system-based Direct ... scenes to investigate how, based on this technology, ...
(Date:5/6/2015)... A recent National Eye Institute (NEI) ... age, is fully endorsed by fresh water advocate Sharon ... Water® radio show. Kleyne notes, however, that the report ... each day. As Founder and Chairman of Bio-Logic Aqua ... Kleyne has extensive knowledge of vision care, dry eye, ...
Breaking Medicine News(10 mins):Health News:Cannibus Industry Start-Up Reaches Profitability While Expanding Its Proprietary Ancillary Medical Marijuana Product IP Portfolio 2Health News:Medicationdiscountcard.com Provides Access to Drug Coupons for Arthritis Awareness Month 2Health News:Medicationdiscountcard.com Provides Access to Drug Coupons for Arthritis Awareness Month 3Health News:Start Planning Now for Long-Term Care, from the May 2015 Harvard Health Letter 2Health News:Novodiax to Be Featured in Upcoming Episode of Innovations TV Series 2Health News:National Eye Institute’s Eye Care as You Age report endorsed by fresh water advocate Sharon Kleyne – with one addition 2Health News:National Eye Institute’s Eye Care as You Age report endorsed by fresh water advocate Sharon Kleyne – with one addition 3
... economy has been "seizing" uncontrollably. Now a Tel Aviv ... economic downturn with the uncontrolled spasms of an epileptic ... the origins of the disaster. In a recent ... Ben-Jacob of Tel Aviv University,s School of Physics and ...
... released online today, a majority of Americans, including most African ... just as other cigarette flavorings have now been banned by ... African American smokers and 24 percent of white smokers smoke ... by the Center for Child and Adolescent Health Policy at ...
... , THURSDAY, May 12 (HealthDay News) -- Italian researchers ... may actually suffer from a psychological condition known as ... is deficient in the enzyme lactase, which breaks down ... bloating, gas, gut pain and nausea when they eat ...
... Researchers at the Stanford University School of Medicine ... naturally occurring "tumor-suppressor" protein works. The separation of these ... could enhance efforts to develop treatment approaches that ... The protein, p53, is mutated or missing in ...
... May 12 (HealthDay News) -- Mind-body therapies such as yoga, ... in mainstream medicine, according to a new study. ... and that number is rising, the researchers noted. They found ... therapy was referred to the treatment by a medical provider. ...
... Amanda Gardner HealthDay Reporter , WEDNESDAY, May 11 ... adults with attention-deficit hyperactivity disorder (ADHD), or the parents of ... finding one that carries the prescription they need to manage ... vary, but much of the focus has been on Adderall ...
Cached Medicine News:Health News:Diagnosing 'seizures' in the US economy 2Health News:African Americans and the general public support banning menthol in cigarettes 2Health News:Lactose Intolerance May Sometimes Be in the Head, Not the Gut 2Health News:Stanford discoveries about tumor-suppressing protein could help to reduce treatment side effects 2Health News:Stanford discoveries about tumor-suppressing protein could help to reduce treatment side effects 3Health News:Doctors Prescribing Meditation, Yoga More Often 2Health News:ADHD Drug Shortage Has Patients, Parents Scrambling 2Health News:ADHD Drug Shortage Has Patients, Parents Scrambling 3
(Date:5/6/2015)... --  Sigma-Aldrich Corporation (NASDAQ: SIAL ) a leading ... $50,000 product donation to the Reproducibility Project: Cancer ... from recent high-impact papers in the field of cancer ... research marketplace Science Exchange , the non-profit ... eLife. The goal of the project is ...
(Date:5/6/2015)... 2015 First programme ... and rilpivirine   ViiV Healthcare ... clinical trial programme to evaluate the safety and ... ) as maintenance therapy for adult patients with ... studies evaluating 48 week viral suppression with a ...
(Date:5/5/2015)... BARCELONA, Spain , May 6, 2015 ... and aspires to lead the European market in the ... Through this alliance ECUPHAR acquires all the assets ... the new organization in the coming weeks. Being both ... not been disclosed.      (Photo: http://photos.prnewswire.com/prnh/20150506/743274 ...
Breaking Medicine Technology:Sigma-Aldrich Donates $50K in Products to the Reproducibility Project to Foster Replicable Research and Accelerate Scientific Discoveries in Cancer Biology 2Sigma-Aldrich Donates $50K in Products to the Reproducibility Project to Foster Replicable Research and Accelerate Scientific Discoveries in Cancer Biology 3ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 2ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 3ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 4ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 5ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 6ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 7ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 8ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 9ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 10ECUPHAR Enters the Spanish and Southern European Markets Through ESTEVE 2
... of its ongoing,efforts to develop research tools that ... disease, The Michael J. Fox,Foundation announced the launch ... the Foundation seeks to drive the creation,and testing ... with a personal,computer and an Internet connection to ...
... March 19 FluoroPharma Inc., a company,developing breakthrough ... (PET) market, announced commencement of Phase,I clinical trials ... the proposed studies. The Phase I trial is ... safety, distribution and dosimetry,of BFPET as a PET ...
Cached Medicine Technology:New Michael J. Fox Foundation Initiative Will Drive Development of Web-Based Tools to Increase Patient Participation in Parkinson's Clinical Trials 2FluoroPharma Announces Commencement of Phase I Clinical Trial for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET) 2
All-natural porcine collagen can be used in open or laparoscopic placement....
... SBI RingFix is a modular external fixation ... large variety of clinical needs. Originally marketed ... has a successful 20 year history of ... Developed around the principles of the Ilizarov ...
... The six models of Thermo Scientific ... mL to 60 mL with very high ... careful design of all components. The Finnpipette ... the extensive Thermo Scientific Finnpipette manual liquid ...
... collection benefits from innovative research in materials ... such as the aerospace and automotive industry, ... and the footwear and textile industry. , ... in the Carrera sunglasses collection to create ...
Medicine Products: